Background Elderly patients with major depression have a poorer prognosis, are less
responsive to treatment, and show greater functional decline compared with younger …

Objective: Esketamine, the S-enantiomer of ketamine, was recently approved as a rapid-
acting intranasal therapy for depression and is currently under development for suicidality …

Background In this post-hoc analysis, data from 2 positive, pivotal, phase 3 trials of
esketamine nasal spray (ESK) in treatment-resistant depression (TRD)—short-term study …

Purpose/Background: Numerous health authority approvals of esketamine nasal spray,
combined with oral antidepressant, to treat depressive symptoms in adults with major …

Background In treatment-resistant depression, commonly defined as a lack of response to
two or more consecutive treatments during the current depressive episode, the percentage …

Objective To present the first real-world data of patients with treatment-resistant depression
(TRD) treated with esketamine through a French cohort Temporary Authorisation for Use …

Background Patients with major depressive disorder who do not respond to≥ 2 different
pharmacological treatments within the current depressive episode are considered to have …

Background An intranasal formulation of esketamine, combined with an oral antidepressant,
is approved in the USA and the European Union for adults with treatment-resistant …

ABSTRACT Introduction: In March 2019, intranasal esketamine was approved by the Food
and Drug Administration (FDA) for the treatment of treatment-resistant depression (TRD) in …

The motive of this article is to review the pharmacological and clinical aspects of esketamine
(ESK), an NMDA-receptor antagonist approved recently by the FDA for treatment-resistant …